Genetic screening for prostate cancer can help identify inherited risks early, guide treatment decisions, and protect your family’s health. At Fred Hutch Cancer Center, we offer expert genetic ...

Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...

New prostate cancer research from an international team led by the Center for Genetic Epidemiology at the Keck School of Medicine of USC has yielded discoveries that could improve screening and ...

The trial design for ARASTEP is highlighted in the following schema: Two special considerations for ARASTEP are that all patients have maximally treated pelvic disease and that metastasis directed ...

While many people are familiar with mammograms and smear tests, prostate screening is talked about far less. Ahead of Prostate Cancer Awareness Month in March, Mr Wissam Abou-Chedid, consultant ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

The UK National Screening Committee (UK NSC) is poised to deliver its recommendations to the Government on Friday regarding expanded prostate cancer screening for men. Currently, the UK lacks a ...

Prostate cancer screening compares favorably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research. The findings are ...

This meta-analysis of 7 trials provides the highest level of evidence to date supporting MDT for selected patients with oligometastatic prostate cancer. Metastasis-directed therapy (MDT) prolongs ...